CAR T cells derived from a novel, high-affinity anti-CLL-1 monoclonal antibody exhibit a significant anti-AML effect.
Saved in:
| Title: | CAR T cells derived from a novel, high-affinity anti-CLL-1 monoclonal antibody exhibit a significant anti-AML effect. |
|---|---|
| Authors: | Kida S; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan.; Department of Hematology and Oncology, Osaka General Medical Center, Osaka, Japan., Suga M; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan., Yamaguchi Y; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan., Ikeda S; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan., Kogue Y; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan.; Osaka Research Center for Drug Discovery, Otsuka Pharmaceutical Company, Ltd., Osaka, Japan., Kawamoto R; Department of Clinical Laboratory and Biomedical Sciences, University of Osaka Graduate School of Medicine, Osaka, Japan., Shibata K; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan., Tsutsumi K; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan., Murakami H; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan., Mizuta E; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan., Mizutani Y; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan., Hosen N; Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan. hnaoki@bldon.med.osaka-u.ac.jp.; World Premier International Immunology Frontier Research Center, University of Osaka, Osaka, Japan. hnaoki@bldon.med.osaka-u.ac.jp.; Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), University of Osaka, Osaka, Japan. hnaoki@bldon.med.osaka-u.ac.jp.; Center for Infectious Disease Education and Research, University of Osaka, Osaka, Japan. hnaoki@bldon.med.osaka-u.ac.jp. |
| Source: | Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2026 Mar 02; Vol. 75 (3). Date of Electronic Publication: 2026 Mar 02. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0851 |
|---|---|
| DOI: | 10.1007/s00262-026-04342-x |
